Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

VRNA Verona Pharma plc

Price (delayed)

$92.495

Market cap

$7.87B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2

Enterprise value

$7.72B

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, ...

Highlights
The company's gross profit has surged by 184% QoQ
Verona Pharma's revenue has soared by 180% from the previous quarter
VRNA's net income has shrunk by 159% YoY but it is up by 5% QoQ
The EPS has dropped by 150% year-on-year but it has grown by 7% since the previous quarter
Verona Pharma's quick ratio has shrunk by 52% YoY and by 19% QoQ
The debt rose by 7% since the previous quarter

Key stats

What are the main financial stats of VRNA
Market
Shares outstanding
85.13M
Market cap
$7.87B
Enterprise value
$7.72B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
34.69
Price to sales (P/S)
66.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
65.1
Earnings
Revenue
$118.54M
Gross profit
$112.55M
Operating income
-$137.75M
Net income
-$163.94M
EBIT
-$122.5M
EBITDA
-$121.41M
Free cash flow
-$121.25M
Per share
EPS
-$2
EPS diluted
-$2
Free cash flow per share
-$1.43
Book value per share
$2.67
Revenue per share
$1.4
TBVPS
$6.19
Balance sheet
Total assets
$525.94M
Total liabilities
$299.34M
Debt
$243.88M
Equity
$226.6M
Working capital
$444.48M
Liquidity
Debt to equity
1.08
Current ratio
8.86
Quick ratio
8.2
Net debt/EBITDA
1.3
Margins
EBITDA margin
-102.4%
Gross margin
94.9%
Net margin
-138.3%
Operating margin
-116.2%
Efficiency
Return on assets
-36.1%
Return on equity
-89.8%
Return on invested capital
-48.4%
Return on capital employed
-26.1%
Return on sales
-103.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VRNA stock price

How has the Verona Pharma stock price performed over time
Intraday
2.72%
1 week
8.13%
1 month
36.97%
1 year
527.08%
YTD
99.17%
QTD
45.68%

Financial performance

How have Verona Pharma's revenue and profit performed over time
Revenue
$118.54M
Gross profit
$112.55M
Operating income
-$137.75M
Net income
-$163.94M
Gross margin
94.9%
Net margin
-138.3%

VRNA financials

The company's gross profit has surged by 184% QoQ
Verona Pharma's revenue has soared by 180% from the previous quarter
VRNA's net income has shrunk by 159% YoY but it is up by 5% QoQ
The operating income has plunged by 90% YoY but it has grown by 11% from the previous quarter

Price vs fundamentals

How does VRNA's price correlate with its fundamentals

VRNA Price vs fundamentals

VRNA Earnings waterfall

VRNA Price vs fair value

Growth

What is Verona Pharma's growth rate over time

VRNA growth chart

Valuation

What is Verona Pharma stock price valuation
P/E
N/A
P/B
34.69
P/S
66.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
65.1

Valuation vs average

Price to earnings (P/E)

The EPS has dropped by 150% year-on-year but it has grown by 7% since the previous quarter

Price to book (P/B)

VRNA's P/B is 106% above its last 4 quarters average of 16.8
VRNA's equity is up by 11% since the previous quarter

Price to sales (P/S)

Verona Pharma's revenue has soared by 180% from the previous quarter

Efficiency

How efficient is Verona Pharma business performance
Verona Pharma's ROA has plunged by 70% YoY but it has increased by 18% from the previous quarter
The return on sales has surged by 69% since the previous quarter
The ROIC has soared by 51% YoY and by 33% from the previous quarter
Verona Pharma's ROE has increased by 6% from the previous quarter

Dividends

What is VRNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRNA.

Financial health

How did Verona Pharma financials performed over time

Assets vs liabilities

Verona Pharma's total assets is 76% more than its total liabilities
Verona Pharma's total assets has soared by 81% YoY and by 11% from the previous quarter
Verona Pharma's current ratio has plunged by 52% YoY and by 17% from the previous quarter

Debt vs equity

The debt is 8% greater than the equity
VRNA's equity is up by 11% since the previous quarter
The debt rose by 7% since the previous quarter

Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.